Literature DB >> 24662470

Two-year outcome of patients after a first hospitalization for heart failure: A national observational study.

Philippe Tuppin1, Anne Cuerq2, Christine de Peretti3, Anne Fagot-Campagna2, Nicolas Danchin4, Yves Juillière5, François Alla2, Hubert Allemand2, Christophe Bauters6, Milou-Daniel Drici6, Albert Hagège6, Guillaume Jondeau6, Patrick Jourdain6, Alain Leizorovicz6, Fred Paccaud6.   

Abstract

BACKGROUND: National population-based management and outcome data for patients of all ages hospitalized for heart failure have rarely been reported. AIM: National population-based management and outcome of patients of all ages hospitalized for heart failure have rarely been reported. The present study reports these results, based on 77% of the French population, for patients hospitalized for the first time for heart failure in 2009.
METHODS: The study population comprised French national health insurance general scheme beneficiaries hospitalized in 2009 with a principal diagnosis of heart failure, after exclusion of those hospitalized for heart failure between 2006 and 2008 or with a chronic disease status for heart failure. Data were collected from the national health insurance information system (SNIIRAM).
RESULTS: A total of 69,958 patients (mean age, 78 years; 48% men) were studied. The hospital mortality rate was 6.4%, with 1-month, 1-year and 2-year survival rates of 89%, 71% and 60%, respectively. Heart failure and all-cause readmission-free rates were 55% and 43% at 1 year and 27% and 17% at 2 years, respectively. Compared with a reference sample of 600,000 subjects, the age- and sex-standardized relative risk of death was 29 (95% confidence interval [CI] 28-29) at 2 years, 82 (95% CI 72-94) in subjects aged<50 years and 3 (95% CI 3-3) in subjects aged ≥ 90 years. For subjects aged < 70 years who survived 1 month after discharge, factors associated with a reduction in the 2-year mortality rate were: female sex; age < 55 years; absence of co-morbidities; and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, lipid-lowering agents or oral anticoagulants during the month following discharge. Poor prognostic factors were treatment with a loop diuretic before or after hospitalization and readmission for heart failure within 1 month after discharge.
CONCLUSIONS: This large population-based study confirms the severe prognosis of heart failure and the need to promote the use of effective medications and management designed to improve survival.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  France; Heart failure; Hospitalisation; Hospitalization; Incidence; Insuffisance cardiaque; SNIIRAM

Mesh:

Substances:

Year:  2014        PMID: 24662470     DOI: 10.1016/j.acvd.2014.01.012

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  21 in total

1.  Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.

Authors:  Patrick Blin; Caroline Dureau-Pournin; Régis Lassalle; Jérémy Jové; Florence Thomas-Delecourt; Cécile Droz-Perroteau; Nicolas Danchin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2017-05-05       Impact factor: 4.335

2.  Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure.

Authors:  Margherita Migone de Amicis; David Chivite; Xavier Corbella; Maria Domenica Cappellini; Francesc Formiga
Journal:  Intern Emerg Med       Date:  2017-02-23       Impact factor: 3.397

3.  Impact of B-lines-guided intensive heart failure management on outcome of discharged heart failure patients with residual B-lines.

Authors:  Yunlong Zhu; Na Li; Mingxing Wu; Zhiliu Peng; Haobo Huang; Wenjiao Zhao; Liqing Yi; Min Liao; Zhican Liu; Yiqun Peng; Yuying Zhou; Jinxin Lu; Guohua Li; Jianping Zeng
Journal:  ESC Heart Fail       Date:  2022-05-20

4.  Predictive risk factors for death in elderly patients after hospitalization for acute heart failure in an internal medicine unit.

Authors:  Camille Roubille; Benjamin Eduin; Cyril Breuker; Laetitia Zerkowski; Simon Letertre; Cédric Mercuzot; Jonathan Bigot; Guilhem Du Cailar; François Roubille; Pierre Fesler
Journal:  Intern Emerg Med       Date:  2022-04-22       Impact factor: 5.472

5.  Hospital readmissions of patients with heart failure: the impact of hospital and primary care organizational factors in Northern Italy.

Authors:  Vera Maria Avaldi; Jacopo Lenzi; Ilaria Castaldini; Stefano Urbinati; Giuseppe Di Pasquale; Mara Morini; Adalgisa Protonotari; Aldo Pietro Maggioni; Maria Pia Fantini
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

6.  Factors associated with prolonged hospitalization, readmission, and death in elderly heart failure patients in western Romania.

Authors:  Istvan Gyalai-Korpos; Oana Ancusa; Tiberiu Dragomir; Mirela Cleopatra Tomescu; Iosif Marincu
Journal:  Clin Interv Aging       Date:  2015-03-11       Impact factor: 4.458

7.  Multi-state modelling of heart failure care path: A population-based investigation from Italy.

Authors:  Francesca Gasperoni; Francesca Ieva; Giulia Barbati; Arjuna Scagnetto; Annamaria Iorio; Gianfranco Sinagra; Andrea Di Lenarda
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

8.  Variation in readmission and mortality following hospitalisation with a diagnosis of heart failure: prospective cohort study using linked data.

Authors:  Rosemary J Korda; Wei Du; Cathy Day; Karen Page; Peter S Macdonald; Emily Banks
Journal:  BMC Health Serv Res       Date:  2017-03-21       Impact factor: 2.655

9.  The Intensity of Primary Care for Heart Failure Patients: A Determinant of Readmissions? The CarPaths Study: A French Region-Wide Analysis.

Authors:  Claire M Duflos; Kamila Solecki; Laurence Papinaud; Vera Georgescu; François Roubille; Gregoire Mercier
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240

10.  Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.

Authors:  Jordi Real; Bogdan Vlacho; Emilio Ortega; Joan Antoni Vallés; Manel Mata-Cases; Esmeralda Castelblanco; Eric T Wittbrodt; Peter Fenici; Mikhail Kosiborod; Dídac Mauricio; Josep Franch-Nadal
Journal:  Cardiovasc Diabetol       Date:  2021-07-09       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.